

Payment System Thwarts Efforts to Treat Obesity

BY MARY ELLEN SCHNEIDER
Senior Writer

With the obesity epidemic growing, physicians are facing a payment system that hasn't caught up.

Although coverage varies by payer, most Medicare carriers do not pay for office visits coded only for obesity, and the same is true for most private payers, physicians told this newspaper.

"The payment mechanism is certainly lagging behind," said Sandra Hassink, M.D., a member of the American Academy of Pediatrics' national task force on obesity and director of the weight management program at the Alfred I. duPont Hospital for Children in Wilmington, Del.

As a result, many physicians find ways to get counseling paid for by coding for related comorbidities such as diabetes or heart disease, said Donna E. Sweet, M.D., chair of the board of regents of the American College of Physicians and professor of internal medicine at the University of Kansas in Wichita.

But that is far from a perfect solution, Dr. Sweet said. If physicians could code for obesity as the primary diagnosis, they could spend less time trying to work around the payment system. Moreover, they could perform early interventions to keep obesity and overweight from leading to diabetes and heart disease, she said.

Barriers to payment for obesity counseling and interventions reflect a larger problem with the episode-driven payment approach. "So much of this revolves

around fixing our payment system," Dr. Sweet said.

But there isn't complete agreement about whether third-party payment for obesity treatment would help patients, said G. Michael Steelman, M.D., a bariatric physician in Oklahoma City and president of the American Society of Bariatric Physicians. Many members of his group are split on this issue, he said.

One side argues that if insurers would pay for this care, patients would seek it out

and stay in treatment. But others say that requiring patients to pay for these services out of pocket provides financial motivation to follow their physician's advice.

"In obesity, there's a lot of work the patients need to do when they leave the office," Steelman observed.

Dr. Steelman said he favors a compromise position in which reimbursement is conditional on some measure of success. For example, payers could cover visits as long as the patient is losing weight or

maintaining weight below a certain point, he said.

The bottom line, Dr. Steelman said, is that insurers will generally be unwilling to invest in obesity interventions until physicians can demonstrate that they are getting results.

In the meantime, physicians should learn how to code so they have the best chance of getting paid for their time, said Jamie Calabrese, M.D., a member of the American Academy of Pediatrics' nation-

Humalog^{mix} 75/25TM

75% insulin lispro protamine suspension
25% insulin lispro injection (rDNA origin)

*What can
your insulin
do for Carl?*



Another Way to Address Obesity

Some physicians have realized that they are limited in what they can accomplish in an office visit so they have started their own weight management programs that incorporate good nutrition and physical activity.

One such physician is David Geller, M.D., a pediatrician in Bedford, Mass., who launched the Early Start program a little over a year ago. The program includes several weeks of medical sessions, nutrition counseling, and structured physical activity.

Dr. Geller said he had grown frustrated with his inability to fully address overweight and obesity issues in his practice. "I just felt there was a better way to address it," he said.

His medical visits with patients are generally well covered by insurance, Dr. Geller said, and they have seen improved coverage since the program began for the nutrition counseling.

Families generally pay out of pocket for the remainder of the costs. "The insurance companies are realizing now that obesity is an issue," Dr. Geller said.

al task force on obesity and medical director of the Children's Institute in Pittsburgh, Pa.

Although most carriers won't pay for interventions that are associated only with obesity, most patients who are obese have other comorbidities. Dr. Calabrese recommends that physicians code the comorbid condition as the primary diagnosis and including obesity as the secondary diagnosis. With that as the starting point, there are multiple ways to code for weight management counseling, she said.

Physicians can use the basic evaluation and management CPT codes, or if the pa-

tient was referred by another professional, the doctor can use the consultation codes. When spending extra time with a patient, physicians should use the prolonged face-to-face codes. The prolonged time codes can be used when the physician goes beyond the usual time for that visit but that time doesn't need to be continuous, Dr. Calabrese said.

Typically, if physicians code accurately, they will get paid fairly, Dr. Calabrese said.

And there is some movement on this issue as some insurers begin to provide payment for the obesity code. There's a potential for a partnership between physi-

cians and payers, who can provide physicians and patients with the tools they need to deal with obesity, she said.

Highmark Inc. of Pittsburgh is doing just that. Starting in January 2006, the health plan will include coverage for obesity interventions as part of its preventive health benefits package. That means that it will begin paying physicians who code for obesity as the primary diagnosis.

This is expected to result in two extra visits a year when coding for obesity alone, said Donald Fischer, M.D., chief medical officer for Highmark Inc. And it will allow the health plan to collect more information on obesity, he said. ■

Reports Compare Health Plans

The National Committee for Quality Assurance has added summary comparative scores to its online "Living with Illness" reports, to help users better compare how health plans help patients manage diabetes, cardiac care, asthma, and mental illness. For a sample report, visit www.healthchoices.org and use "See How Your Health Plan Rates."

Humalog® Mix75/25™ provides both fasting and postprandial control from the start

More than twice as many patients on Humalog Mix75/25 plus metformin reached an A1C \leq 7% compared to patients on glargine plus metformin (30% vs 12%).*†

- Primary end point for this trial is a change in A1C at the end of the treatment period. There was a 1 percentage point reduction with Humalog Mix75/25 and a 0.42 percentage point reduction with glargine.
- Overall hypoglycemia rate and nocturnal hypoglycemia rate were not different between the two treatment groups.¹

For more information, visit startinginsulin.com

Provides Both Fasting and Postprandial Control

Humalog Mix75/25 is for use in patients with diabetes mellitus for the control of hyperglycemia.

Important Safety Information

Humalog differs from regular human insulin by its rapid onset of action as well as a shorter duration of activity. Therefore, the dose of Humalog Mix75/25 should be given within 15 minutes before a meal.

Humalog or Humalog Mix75/25 is contraindicated during episodes of hypoglycemia and in patients sensitive to Humalog or any excipients contained in the formulation. Safety and effectiveness of Humalog Mix75/25 in patients less than 18 years of age have not been established. There are no adequate and well-controlled clinical studies of the use of Humalog or Humalog Mix75/25 in pregnancy or nursing mothers.

Simple to Start

Potential side effects associated with the use of all insulins include hypoglycemia, weight gain, hypokalemia, lipodystrophy, and hypersensitivity. Because of the difference in action of Humalog, care should be taken in patients in whom these conditions may be clinically relevant (eg, those who are fasting, have autonomic neuropathy or renal impairment, are using potassium-lowering drugs, or taking drugs sensitive to serum potassium level). **Patients should be advised not to mix Humalog Mix75/25 with another insulin. Starting or changing insulin therapy should be done cautiously and only under medical supervision.**

Humalog® Mix75/25™ is a trademark of Eli Lilly and Company.

Humalog Mix75/25 is available by prescription only.

Please see reverse side for brief summary of Prescribing Information.

Easy-to-use Pen

* An open-label, randomized, crossover trial of 97 patients with type 2 diabetes inadequately controlled on once- or twice-daily insulin alone or in combination with other oral agents

† PAIR-PI average daily dose of insulin for Humalog Mix75/25 vs glargine: 0.42 ± 0.20 vs 0.36 ± 0.18

Reference:

1. Malone JK et al. Combined therapy with insulin lispro mix 75/25 plus metformin or insulin glargine plus metformin. *Clin Ther.* 2004;26(12):2034-2044.